- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Timothy Murphy Discusses Successfully Implementing Biosimilars Into Community Cancer Practice
Having a plan in place to educate providers and the pharmacy team has contributed to the success that Rocky Mountain Cancer Centers (RMCC) has had with rapidly implementing biosimilars, said Timothy Murphy, MD, medical oncologist/hematologist with RMCC.
Having a plan in place to educate providers and the pharmacy team has contributed to the success that Rocky Mountain Cancer Centers (RMCC) had with rapidly implementing biosimilars, said Timothy Murphy, MD, medical oncologist/hematologist with RMCC.
Transcript
How is Rocky Mountain Cancer Centers utilizing biosimilars?
So, RMCC as a community cancer center was probably a bit ahead of the curve with biosimilars, and it's because of our relationship with the national network of US Oncology. We did have sort of line of sight of this biosimilar transformation that was coming down the pike. We had to institute, fairly rapidly, an education program for our providers. We had to convince our providers that switching the drugs that they have written for with a biosimilar was an OK thing to do, that these medications are just as efficacious as the name brand drugs that they may have actually written for it. So, that took an educational program, kind of a system, to get going.
And once we had buy-in from the providers that the biosimilars were essentially equivalent drugs to the innovator drugs, then then it really fell to our pharmacy team. You really have to have a strong pharmacy team—clinical pharmacist, pharm techs—we had to educate the nurses on how to infuse these medicines. The pharmacy team was the key to actually implementing that rapid transformation that we were fairly successful with.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More
